Edison Issues Update on Quantum Genomics (ALQGC)

LONDON, UK / ACCESWIRE / April 1, 2019 / Quantum Genomics (PARIS: ALQGC) recently reported its 2018 annual results and updated development timelines. Results from the pharmacokinetic study of sustained-release (once per day) firibastat as well as the initiation of the 294-patient Phase IIb QUORUM study in heart failure are both expected in Q219. The company is also planning to initiate its Phase III trial hypertension in H219. In addition, it is currently in discussions with a number of potential partners for the firibastat programme following the strong NEW-HOPE data.

We have adjusted our valuation of Quantum Genomics to €860m or €52.43 per share from €803m or €66.91 per share. The total valuation has increased due to rolling forward our NPVs and a higher net cash level, while the valuation per share has decreased due to a higher share count as the company utilised an equity line with Kepler Cheuvreux. Quantum had €14.8m in cash at end 2018 and has utilised an additional €2.6m of its equity line since then, which should fund the company’s trials to the end of 2019.

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Maxim Jacobs, +1 646 653 7027
Briana Warschun, +1 646 653 7031

Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn https://www.linkedin.com/company/edison-investment-research
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv

SOURCE: Quantum Genomics (ALQGC)

View source version on accesswire.com:

error: Content is protected !!